Paul Capital invests in Indian drugmaker

The US-based firm will use its royalty fund to help the company develop a US portfolio of dermatology drugs.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this